Elamex S.A. de CV

Elamex SA de CV engages in candy manufacturing, and nut processing and packaging in the United States and Mexico. It produces sugar candies, such as starlight mints, orange slices, spice drops, jelly beans, and gummies. The company also processes packaged nuts, including pecans, walnuts, and almonds; and bulk foodservice items, such as sunflower seeds and trail mixes. In addition, it offers contract manufacturing services for food products; and warehousing and logistics services. Further, the company engages in real estate holdings in Mexico. It sells sugar candies through grocery, drug, mass merchant, food service, and convenience channels; and markets and distributes packaged nuts to foodservice and retail markets. The company serves restaurants, healthcare facilities, hotels, schools, and colleges. Elamex SA de CV was founded in 1973 and is headquartered in El Paso, Texas. It has operations in Mexico and the United States. The company has a distribution center in El Paso, Texas.

Elamex S.A. de CV trades as ELAMF on OTC. The company is classified in Consumer Defensive / Packaged Foods and reports in USD.

The current profile places the business in Packaged Foods. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Elamex S.A. de CV can be compared against peers such as BioForce Nanosciences Holdings, Inc., Big Rock Brewery Inc., Cellev8 Nutrition Inc., China Foods Holdings Ltd., Colabor Group Inc., Clean Seas Seafood Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $21.75M, beta of 0.32, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ELAMF currently shows total debt of N/A and beta of 0.32. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.elamex.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.